Nonmelanoma skin cancer is the most common cancer in the United States. However, advanced forms of nonmelanoma skin cancer that require systemic treatments are uncommon. Because cancer immunotherapy is used more routinely to treat advanced nonmelanoma skin cancer, the Society for Immunotherapy of Cancer convened an expert panel to develop clinical practice guidelines for its use. This article provides guidance to clinicians treating people with nonmelanoma skin cancer.

What is exciting about this article?

Most community oncologists treat only a small number of nonmelanoma skin cancers every year. To help address common questions when using immunotherapy to treat nonmelanoma skin cancers, this report summarizes a set of clinical practice guidelines based on published data and expert opinions. These guidelines will be updated regularly to remain current with practice standards and will serve as a reference to practicing oncologists for optimal patient care.

How does this fit into the larger NIAMS portfolio?

Skin cancer is a disease of notable public health concern with one in five Americans developing skin cancer before age 70. This article provides helpful guidance to clinicians treating people with nonmelanoma skin cancer.

Grant support


Research Areas:

Cancer Biology Computational Biology Skin Biology


Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I
J Immunother Cancer.
2022 Jul;
doi: 10.1136/jitc-2021-004434
PMID: 35902131

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.